ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Group PLC VISITECT CD4 development update (6474O)

21/05/2018 7:00am

UK Regulatory


Omega Diagnostics (LSE:ODX)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Omega Diagnostics Charts.

TIDMODX

RNS Number : 6474O

Omega Diagnostics Group PLC

21 May 2018

Omega Diagnostics Group PLC

("Omega" or "the Company" or the "Group")

VISITECT(R) CD4 development update

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following update with its VISITECT(R) CD4 development programme.

Further to the announcement on 10 April 2018, the Company recently held a design review meeting for its VISITECT(R) CD4 test for identifying advanced HIV disease*. The Company confirms that results from feasibility testing show acceptable performance against design goals and accordingly, the Company has progressed into a formal optimisation phase within its design control programme.

Colin King, CEO of Omega commented: "I am pleased to report we have achieved this key milestone as promised and that our product aligns with our design specifications. This enhancement to our 350 test line is crucial in managing patients with advanced diseases and one that the NGO community are keen to see brought to the market. I look forward to making further announcements as we bring this product to market."

* defined as those patients with lower than 200 CD4+ T cells per microlitre of blood

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contacts:

 
 Omega Diagnostics Group             Tel: 01259 763 030 
  PLC 
 Colin King, Chief Executive   www.omegadiagnostics.com 
 Kieron Harbinson, Group 
  Finance Director 
 
 finnCap Ltd                         Tel: 020 7220 0500 
 Geoff Nash/James Thompson 
  (Corporate Finance) 
 Camille Gochez/ Abigail 
  Wayne (Corporate Broking) 
 
 Walbrook PR Limited              Tel: 020 7933 8780 or 
                                   omega@walbrookpr.com 
 Paul McManus                        Mob: 07980 541 893 
 Lianne Cawthorne                    Mob: 07584 391 303 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCURSKRWRAVURR

(END) Dow Jones Newswires

May 21, 2018 02:00 ET (06:00 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Your Recent History

Delayed Upgrade Clock